InsiderSignal.AI

InsiderSignal.ai

JSPR - Jasper Therapeutics, Inc.

Insider Purchase by Lucas Svetlana (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Lucas Svetlana, serving as Dir at Jasper Therapeutics, Inc. (JSPR), purchased 20,000 shares at $2.43 per share, for a total transaction value of $48,600.00. Following this transaction, Lucas Svetlana now holds 20,000 shares of JSPR.

The trade was executed on Monday, September 22, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, September 24, 2025, 2 days after the trade was made.

Jasper Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Lucas Svetlana

Dir

Svetlana Lucas, Ph.D. is an independent Class III Director at Jasper Therapeutics, Inc. (NASDAQ: JSPR), serving since June 2024, and a member of the Nominating & Corporate Governance Committee.[[1]](https://fintool.com/app/research/companies/JSPR/people/svetlana-lucas)[[2]](https://jaspertx.com/team-members/svetlana-lucas-ph-d/) With over 20 years of experience in strategy, business development, and commercialization in immunology and oncology, she recently purchased 20,000 shares of JSPR common stock at $2.43 per share (totaling $48,600) and 20,000 common stock warrants on September 22, 2025.[[3]](https://www.investing.com/news/insider-trading-news/jasper-therapeutics-director-lucas-buys-48600-in-stock-93CH-4254022) Dr. Lucas earned her Ph.D. in Molecular Biology & Biochemistry from the California Institute of Technology (Caltech) and an undergraduate degree in Biology from Moscow State University.[[1]](https://fintool.com/app/research/companies/JSPR/people/svetlana-lucas)[[2]](https://jaspertx.com/team-members/svetlana-lucas-ph-d/) Her career highlights include serving as Chief Business Officer at Scribe Therapeutics since June 2019, where she led strategic collaborations with Sanofi and Eli Lilly’s Prevail Therapeutics; Senior Vice President of Business Development at Tizona Therapeutics, driving a global deal with AbbVie; Head of Oncology & Inflammation External R&D at Amgen, overseeing the Kite Pharma collaboration; and roles at Onyx Pharmaceuticals, PDL BioPharma/Facet Biotech, XOMA, and McKinsey & Company.[[1]](https://fintool.com/app/research/companies/JSPR/people/svetlana-lucas)[[2]](https://jaspertx.com/team-members/svetlana-lucas-ph-d/) She currently serves on the Board of Directors at aTyr Pharma, Inc. (NASDAQ: ATYR) since June 2019 and as an Advisor to Radar Therapeutics since October 2023.[[1]](https://fintool.com/app/research/companies/JSPR/people/svetlana-lucas)[[2]](https://jaspertx.com/team-members/svetlana-lucas-ph-d/)

View full insider profile →

Trade Price

$2.43

Quantity

20,000

Total Value

$48,600.00

Shares Owned

20,000

Trade Date

Monday, September 22, 2025

153 days ago

SEC Filing Date

Wednesday, September 24, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Jasper Therapeutics, Inc.

Company Overview

No company information available
View news mentioning JSPR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/476524

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime